The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation

ABSTRACT

The detection and quantification of factor VIII (FVIII) inhibitors is clinically important both for the identification of hemophilia A patients with inhibitors and for the management of immune tolerance treatment. Only limited data are available on the between-laboratory variation of FVIII inhibitor testing. This report describes the evaluation of the results of the large-scale external quality assessment program of the European Concerted Action on Thrombosis Foundation. This study includes the results of six different surveys for the period 2006 to 2008 with 100 to 170 participating laboratories. The overall between-laboratory variation ranged from 28% to 52% with a slightly lower variation for the Nijmegen assay (~39%) on average than for the Bethesda assay (~45%). The use of buffered normal pooled plasma as FVIII source showed better performance compared with the use of nonbuffered pooled plasma; likewise the use of FVIII-deficient plasma compared with the use of imidazole buffer. However, the combination of both was essential for lowest between-laboratory variation. The Nijmegen assay also showed better performance with respect to specificity and sensitivity than the Bethesda assay, although the results for neither were entirely satisfactory. In general, it can be concluded that the measurement of FVIII inhibitory antibodies with the Nijmegen assay should be favored over the use of the Bethesda assay. However, further improvement of the laboratory test for FVIII inhibitors is urgently needed.

KEYWORDS

Between-laboratory variation - factor VIII inhibitors - Bethesda assay - Nijmegen assay

REFERENCES

• 1 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9(4) 418-435
• 2 Kasper C K, Aledort L, Aronson D et al.. Proceedings: a more uniform measurement of factor VIII inhibitors.  Thromb Diath Haemorrh. 1975;  34(2) 612
• 3 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.  Thromb Haemost. 1995;  73(2) 247-251
• 4 Giles A R, Verbruggen B, Rivard G E, Teitel J, Walker I. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis . A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada.  Thromb Haemost. 1998;  79(4) 872-875
• 5 Verbruggen B, Novakova I, van Heerde W. Detecting and qualifying functional inhibitors in hemostasis. In: Kitchen S, Olson JD, Preston EF Quality in Laboratory Hemostasis and Thrombosis. Oxford, United Kingdom; Blackwell 2009: 198-207
• 6 Reber G, Aurousseau M H, Dreyfus M et al.. Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas.  Haemophilia. 1999;  5(4) 292-293
• 7 Favaloro E J, Bonar R, Duncan E RCPA QAP in Haematology Haemostasis Committee et al. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.  Thromb Haemost. 2006;  96(1) 73-78
• 8 Peerschke E I, Castellone D D, Ledford-Kraemer M, Van Cott E M, Meijer P. NASCOLA Proficiency Testing Committee . Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.  Am J Clin Pathol. 2009;  131(4) 552-558
• 9 van den Brink E N, Turenhout E A, Bank C M, Fijnvandraat K, Peters M, Voorberg J. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain.  Blood. 2000;  96(2) 540-545
• 10 Bland J M, Altman D G. Statistical methods for assessing agreement between two methods of clinical measurement.  Lancet. 1986;  1(8476) 307-310
• 11 Bland J M, Altman D G. Comparing methods of measurement: why plotting difference against standard method is misleading.  Lancet. 1995;  346(8982) 1085-1087
• 12 Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay.  Thromb Haemost. 2002;  88(2) 362-364
• 13 Verbruggen B, Meijer P, Novákova I, Van Heerde W. Diagnosis of factor VIII deficiency.  Haemophilia. 2008;  14(suppl 3) 76-82
• 14 Mariani G, Siragusa S, Kroner B L. Immune tolerance induction in hemophilia A: a review.  Semin Thromb Hemost. 2003;  29(1) 69-76
• 15 Smith O P. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.  Pathophysiol Haemost Thromb. 2002;  32(Suppl 1) 22-25